FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000500437> ?p ?o ?g. }

• W2000500437 endingPage "P4864" @default.
• W2000500437 startingPage "P4864" @default.
• W2000500437 abstract "Background: For patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) current guidelines recommend antithrombotic therapy with new P2Y12 receptor antagonists (prasugrel and ticagrelor) as well as bivalirudin. Currently, there is limited long term experience with the combination of these 2 therapeutic options. Methods: Between May 2010 and November 2011, we identified 359 consecutive patients with ACS undergoing PCI, who were preloaded with either prasugrel or ticagrelor and received bivalirudin during PCI. Patients were preloaded as soon as possible before coronary angiography and PCI. The loading dose for prasugrel was 60 mg and for ticagrelor 180 mg. Immediately before PCI patients were treated with bivalirudin loading dose and with infusion during the PCI. Post PCI dual antiplatelet therapy was continued for 12 months independent of type of implanted stent. The 1 year incidences of death from any cause, the composite of death and myocardial infarction (MI) and of target vessel revascularisation (TVR) were analyzed. Results: One year follow-up was complete in all patients. Patients were 65 + 12 years old (patients with ticagrelor were in average 11 years older), 22% of patients were diabetic. STEMI patients were more frequent (70.8%) than NSTEMI patients (29.2%). With prasugrel were treated 87.0% of STEMI patients and with ticagrelor 71.4% of NSTEMI patients. Bail-out GP IIbIIIa –inhibitors were needed in 8.3%. The 1 year incidence of TVR was 16.1% in the prasugrel group and 13.9% in the ticagrelor group, those of death and MI 7.3% and 10.6% and those of death 6.5% and 8.6%, respectively. There was no case of subacute stent thrombosis. TIMI major bleeding occurred in 0.8% and only 1.1% of the patients needed blood transfusion. There were no significant differences between ticagrelor and prasugrel in any of the event rates. Conclusions: In patients with ACS undergoing PCI the combination of new generation P2Y12-selective inhibitors (prasugrel or ticagrelor) and bivalirudin is associated with low rates of severe bleeding complications and similar clinical outcome during 1 year follow-up between in the prasugrel and ticagrelor treatment group." @default.
• W2000500437 created "2016-06-24" @default.
• W2000500437 creator A5007785874 @default.
• W2000500437 creator A5018845197 @default.
• W2000500437 creator A5062252910 @default.
• W2000500437 creator A5070103202 @default.
• W2000500437 creator A5078602431 @default.
• W2000500437 creator A5086210066 @default.
• W2000500437 creator A5089531887 @default.
• W2000500437 date "2013-08-02" @default.
• W2000500437 modified "2023-10-18" @default.
• W2000500437 title "Combined therapy with new P2Y12 receptor antagonists (prasugrel and ticagrelor) and bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention" @default.
• W2000500437 doi "https://doi.org/10.1093/eurheartj/eht310.p4864" @default.
• W2000500437 hasPublicationYear "2013" @default.
• W2000500437 type Work @default.
• W2000500437 sameAs 2000500437 @default.
• W2000500437 citedByCount "1" @default.
• W2000500437 countsByYear W20005004372015 @default.
• W2000500437 crossrefType "journal-article" @default.
• W2000500437 hasAuthorship W2000500437A5007785874 @default.
• W2000500437 hasAuthorship W2000500437A5018845197 @default.
• W2000500437 hasAuthorship W2000500437A5062252910 @default.
• W2000500437 hasAuthorship W2000500437A5070103202 @default.
• W2000500437 hasAuthorship W2000500437A5078602431 @default.
• W2000500437 hasAuthorship W2000500437A5086210066 @default.
• W2000500437 hasAuthorship W2000500437A5089531887 @default.
• W2000500437 hasBestOaLocation W20005004371 @default.
• W2000500437 hasConcept C126322002 @default.
• W2000500437 hasConcept C164705383 @default.
• W2000500437 hasConcept C2777028646 @default.
• W2000500437 hasConcept C2777565915 @default.
• W2000500437 hasConcept C2777698277 @default.
• W2000500437 hasConcept C2780400711 @default.
• W2000500437 hasConcept C2780890252 @default.
• W2000500437 hasConcept C45393284 @default.
• W2000500437 hasConcept C500558357 @default.
• W2000500437 hasConcept C71924100 @default.
• W2000500437 hasConceptScore W2000500437C126322002 @default.
• W2000500437 hasConceptScore W2000500437C164705383 @default.
• W2000500437 hasConceptScore W2000500437C2777028646 @default.
• W2000500437 hasConceptScore W2000500437C2777565915 @default.
• W2000500437 hasConceptScore W2000500437C2777698277 @default.
• W2000500437 hasConceptScore W2000500437C2780400711 @default.
• W2000500437 hasConceptScore W2000500437C2780890252 @default.
• W2000500437 hasConceptScore W2000500437C45393284 @default.
• W2000500437 hasConceptScore W2000500437C500558357 @default.
• W2000500437 hasConceptScore W2000500437C71924100 @default.
• W2000500437 hasIssue "suppl 1" @default.
• W2000500437 hasLocation W20005004371 @default.
• W2000500437 hasOpenAccess W2000500437 @default.
• W2000500437 hasPrimaryLocation W20005004371 @default.
• W2000500437 hasRelatedWork W1789533759 @default.
• W2000500437 hasRelatedWork W1983992557 @default.
• W2000500437 hasRelatedWork W2256000712 @default.
• W2000500437 hasRelatedWork W2369639111 @default.
• W2000500437 hasRelatedWork W2506099086 @default.
• W2000500437 hasRelatedWork W2597134625 @default.
• W2000500437 hasRelatedWork W2790813266 @default.
• W2000500437 hasRelatedWork W2804083793 @default.
• W2000500437 hasRelatedWork W4313530012 @default.
• W2000500437 hasRelatedWork W4366819616 @default.
• W2000500437 hasVolume "34" @default.
• W2000500437 isParatext "false" @default.
• W2000500437 isRetracted "false" @default.
• W2000500437 magId "2000500437" @default.
• W2000500437 workType "article" @default.